To evaluate whether garlicin post-conditioning can attenuate myocardial ischemiareperfusion injury in a catheter-based porcine model of acute myocardial infarction (AMI) by affecting adhesion molecules integrin β1/CD29 and platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31).
Twenty-two swine were devided into 3 groups: 6 in a sham-operation group, and 8 each in the model and garlicin groups. AMI porcine model was established in the model and garlicin groups. The distal parts of the left anterior descending coronary artery in the animals of the model and garlicin groups were occluded by dilated balloon for 2 h, followed by reperfusion for 3 h. Garlicin (1.88 mg/kg) was injected over a period of 1 h, beginning just before reperfusion, in the garlicin group. Real-time polymerase chain reaction, immunohistochemistry and Western blot were carried out to detect mRNA and protein expressions of CD29 and CD31 3 h after reperfusion.
Hematoxylin-eosin staining showed a better myocardial structure in the garlicin group after reperfusion. Compared to the model group, garlicin inhibited both the mRNA and protein expression of CD29 and CD31 in reperfusion area and no-reflflow area (P<0.05 respectively).
Garlicin post-conditioning induced cardio-protection against myocardial ischemia-reperfusion injury in this catheter-based porcine model of AMI. The cardio-protective effect of garlicin is possibly owing to suppression of production of CD29 and CD31, by inhibition of the mRNA expression of CD29 and CD31.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Hausenloy D J. Cardiopro tection techniques: preconditioning, postconditioning and remote conditioning. Curr Pham Des 2013;19:4544–4563.
Predmore BL, Kondo K, Bhushan S, Zlatopolsky MA, King AL, Aragon JP, et al. The polysulfide diallyltrisulfide protects the ischemic myocardium by preservation of endogenous hydrogen sulfide and increasing nitric oxide bioavailability. Am J Physiol Heart Circ Physiol 2012;302:H2410–H2418.
Peyman M, Surush M, Milad M, Shahin A, Shadi S. Therapeutic uses and pharmacological properties of garlic, shallot, and their biologically active compounds. Iran J Basic Med Sci 2013;10:1031–1048.
Varshney R, Budoff MJ. Garlic and heart disease. J Nutr 2016;146(Suppl):416S–21S.
Khatua TN, Adela R, Banerjee SK. Garlic and cardioprotection: insights into the molecular mechanisms. Can J Physiol Pharmacol 2013;91:448–458.
Bradley JM, Organ CL, Lefer DJ. Garlic-derived organic polysulfides and myocardial protection. J Nutr 2016;146(Suppl):403S–409S.
Sharma AK, Munajjam A, Vaishnav B, Sharma R, Sharma A, Kishore K, et al. Involvement of adenosine and standardization of aqueous extract of garlic (Allium sativum Linn.) on cardioprotective and cardiodepressant properties in ischemic preconditioning and myocardial ischemia-reperfusion induced cardiac injury. J Biomed Res 2012;26:24–36.
Li JH, Yang P, Li AL, Wang Y, Shi ZX, Ke YN, et al. The preventive effect of garlicin on a porcine model of myocardial infarction reperfusion no-reflow. Chin J Integr Med 2014;20:425–429.
Yang P, Li JH, Li AL, Wang Y, Shi ZX, Ke YN, et al. Garlicin attenuates reperfusion no-reflow in a catheter-based porcine model of acute myocardial infarction. Artif Cells Blood Substit Immobil Biotechnol 2012;40:285–289.
Suzuki Y, Lyons JK, Yeung AC, Ikeno F. In vivo porcine model of reperfused myocardial infarction: in situ double staining to measure precise infarct area/area at risk. Catheteriz Cardiovasc Interv 2008;71:100–107.
Haverslag R, Pasterkamp G, Hoefer IE. Targeting adhesion molecules in cardiovascular disorders. Cardiovasc Hematol Disord Drug Targets 2008;8:252–260.
Supported by Beijing Natural Science Foundation, China (No. 7152128)
About this article
Cite this article
Yang, P., Li, J., Li, A. et al. Garlicin Post-Conditioning Suppresses Adhesion Molecules in a Porcine Model of Myocardial Ischemia-Reperfusion Injury. Chin. J. Integr. Med. 25, 31–36 (2019). https://doi.org/10.1007/s11655-017-2757-5
- reperfusion injury
- myocardial infarction